RLYB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rallybio Corp (RLYB) is not a strong buy at the moment given the lack of positive catalysts, no significant trading signals, and a mixed financial performance. While the company has shown strong revenue growth, its net income and EPS have significantly declined. The technical indicators are neutral, and there is no recent news or significant trading activity to suggest a compelling entry point. For a beginner investor with a long-term strategy, it is advisable to wait for clearer signals or stronger fundamentals before investing.
The technical indicators for RLYB are neutral. The MACD is below 0 and negatively contracting, indicating weak momentum. The RSI is in the neutral zone at 48.797, and the moving averages are converging, showing no clear trend. The stock is trading near its pivot level (8.238) with support at 8.028 and resistance at 8.448.
Revenue increased by 484.21% YoY in Q4 2025, showing strong top-line growth. Gross margin remains at 100%.
Net income dropped by -47.01% YoY, and EPS declined by -47.98% YoY, indicating worsening profitability. No significant news, trading trends, or congressional activity to act as a catalyst.
In Q4 2025, Rallybio Corp reported a revenue increase of 484.21% YoY to $222,000. However, net income dropped to -$5,852,000 (-47.01% YoY), and EPS fell to -1.03 (-47.98% YoY). Gross margin remained stable at 100%.
No recent analyst ratings or price target changes are available for RLYB.
